Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
Status:
Completed
Trial end date:
2017-09-26
Target enrollment:
Participant gender:
Summary
This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG,
Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and
well-tolerated treatment for HIV. DTG is a type of HIV medicine called an integrase
inhibitor; 3TC is a type of HIV medicine called a reverse transcriptase inhibitor. DTG works
by blocking integrase and 3TC works by blocking reverse transcriptase, two HIV proteins
(enzymes). This prevents HIV from multiplying and lowers the viral load (amount of HIV in the
blood). Both DTG and 3TC are currently part of Food and Drug Administration (FDA) recommended
regimens along with a third active drug. Since some HIV medicines have side effects and are
costly, there is interest in whether HIV can be successfully controlled with fewer than three
HIV drugs.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)